Longevity Pharmaceuticals

Low-Dose Naltrexone (LDN)

FDA approved

Off-label utility player — autoimmune modulation, pain reduction, HPA-axis support.

Open in AppAsk AI Advisor

Mechanism

Opioid antagonist (low-dose paradoxical). Off-label utility player — autoimmune modulation, pain reduction, HPA-axis support. For full mechanism, dosing protocol, and stacking guidance, ask the AI Advisor or open the compound in-app.

Peer-Reviewed Studies (2)

Low-Dose Naltrexone for Fibromyalgia RCT

Arthritis Rheum · 2013

LDN reduced pain scores significantly more than placebo.

PubMed PMID 23359310 →

Low-Dose Naltrexone for Crohn's Disease Pilot

Am J Gastroenterol · 2007

67% achieved clinical response on LDN.

PubMed PMID 17222320 →

Related Compounds

Rapamycin

The only molecule shown to extend lifespan in every species tested — yeast to mammals.

Metformin

Most-prescribed diabetes drug, repurposed as the first FDA-approved aging trial.

Acarbose

Lifespan-extending diabetes drug — slows carb absorption, blunts post-meal glucose.

SGLT2 Inhibitors (Empagliflozin)

Diabetes drug with off-label longevity interest — cardiac, renal, metabolic benefits.

Telmisartan

ARB blood pressure med with PPARγ activity — investigational longevity application.

Doxycycline (low-dose)

MMP modulator at sub-antibiotic dose — connective tissue, periodontal support.